1. Discovery of a Small Molecule Activator of Slack (Kcnt1) Potassium Channels That Significantly Reduces Scratching in Mouse Models of Histamine‐Independent and Chronic Itch.
- Author
-
Balzulat, Annika, Zhu, W. Felix, Flauaus, Cathrin, Hernandez‐Olmos, Victor, Heering, Jan, Sethumadhavan, Sunesh, Dubiel, Mariam, Frank, Annika, Menge, Amelie, Hebchen, Maureen, Metzner, Katharina, Lu, Ruirui, Lukowski, Robert, Ruth, Peter, Knapp, Stefan, Müller, Susanne, Steinhilber, Dieter, Hänelt, Inga, Stark, Holger, and Proschak, Ewgenij
- Subjects
- *
ITCHING , *POTASSIUM channels , *SMALL molecules , *DOPAMINE , *LABORATORY mice , *SENSORY neurons , *ANTIPSYCHOTIC agents - Abstract
Various disorders are accompanied by histamine‐independent itching, which is often resistant to the currently available therapies. Here, it is reported that the pharmacological activation of Slack (Kcnt1, KNa1.1), a potassium channel highly expressed in itch‐sensitive sensory neurons, has therapeutic potential for the treatment of itching. Based on the Slack‐activating antipsychotic drug, loxapine, a series of new derivatives with improved pharmacodynamic and pharmacokinetic profiles is designed that enables to validate Slack as a pharmacological target in vivo. One of these new Slack activators, compound 6, exhibits negligible dopamine D2 and D3 receptor binding, unlike loxapine. Notably, compound 6 displays potent on‐target antipruritic activity in multiple mouse models of acute histamine‐independent and chronic itch without motor side effects. These properties make compound 6 a lead molecule for the development of new antipruritic therapies targeting Slack. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF